DUSP26 activity leads to increased chemoresistance to doxorubicin and VP-16 (etoposide) treatment, and overexpression was seen in high-risk NB tumor tissue samples correlating with a worse prognosis in these patients. The gene discussed is DUSP26; the disease is neoplasm.